Sinofn Health
Sinofn Health
In the global nutraceutical market, the distinction between Ubiquinone (oxidized CoQ10) and Ubiquinol (reduced CoQ10) is paramount for brands aiming for clinical efficacy. As a leading OEM/ODM manufacturer, SINOFN Health prioritizes the integration of evidence-based formulations.
Ubiquinone is the traditional form of Coenzyme Q10. It is stable and cost-effective, making it the industry standard for general wellness supplements. However, human physiological conversion of Ubiquinone into its active, antioxidant form—Ubiquinol—diminishes with age, stress, and specific metabolic conditions.
Ubiquinol represents the "active" form, offering superior bioavailability. Our proprietary manufacturing processes at SINOFN ensure that Ubiquinol remains protected from oxidation, delivering the mitochondrial support that aging consumers demand. For brands looking to capture the "Premium Heart Health" or "Anti-Aging" market segments, choosing the right manufacturer with stability-testing expertise is not optional—it is critical.
The demand for high-purity CoQ10 is surging, driven by the global aging population and the rise of "Longevity" biohacking trends. Global procurers are shifting from low-cost, low-efficacy ingredients to high-bioavailability formulations. China’s manufacturing efficiency, led by facilities like SINOFN, allows for the scale-up of these sensitive production processes (softgels and specialized lipid-based emulsions) at a fraction of Western costs while maintaining rigorous FSSC 22000 and HACCP standards.
Efficiency in the supply chain is no longer just about price; it’s about speed-to-market and R&D collaboration. SINOFN leverages deep ties with the Chinese Academy of Sciences, allowing us to rapidly prototype new delivery systems, such as enhanced-absorption softgels or liquid-dispersion technologies that outperform standard tableted forms.
SINOFN Health Co., Ltd. is the dedicated supplement OEM manufacturing division of SINOFN Group – a national high-tech enterprise founded in 2012 and backed by the Chinese Academy of Sciences. Established in 2025, we operate from Shanghai as the trading hub for global partners seeking premium, science-driven contract manufacturing services.
Dr. Tan Shengjie (Ph.D Peking University) leads our metabolic disorder formulations, ensuring our CoQ10 line meets clinical-grade standards.
Dr. Zhang Ying (CAS Postdoc) specializes in bioactive compound delivery, crucial for keeping Ubiquinol stable during production.
Hans van Dijk (Netherlands) brings EU regulatory expertise to our global manufacturing protocols.
10+ lines (softgels, gummies, powders) with 500M+ annual capacity.
HPLC/GC-MS testing for guaranteed purity and contaminant screening.
Bioavailability optimization studies for new nutraceutical breakthroughs.
Full-plant integration with batch traceability for every unit produced.
Production Facility
Capital (RMB)
Patents Held
Trademarks
A: Manufacturing Ubiquinol requires sophisticated oxygen-free environments to prevent oxidation. SINOFN utilizes advanced encapsulation technologies to ensure the product remains in its reduced, bioavailable state until ingestion.
A: Yes, we provide pilot-scale prototyping. We bridge the gap between initial concept and mass-market manufacturing to help brands test their formulations efficiently.
A: We are certified with ISO9001, ISO22000, HACCP, and HALAL, ensuring our products meet global safety standards for entry into diverse international markets.
